A detailed history of Vanguard Group Inc transactions in Allakos Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,514,345 shares of ALLK stock, worth $3.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,514,345
Previous 3,514,345 -0.0%
Holding current value
$3.3 Million
Previous $3.51 Million 35.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$1.0 - $1.45 $280,384 - $406,556
-280,384 Reduced 7.39%
3,514,345 $3.51 Million
Q1 2024

May 10, 2024

BUY
$1.02 - $3.23 $549,868 - $1.74 Million
539,087 Added 16.56%
3,794,729 $4.78 Million
Q4 2023

Feb 14, 2024

SELL
$1.72 - $3.18 $17,181 - $31,765
-9,989 Reduced 0.31%
3,255,642 $8.89 Million
Q3 2023

Nov 14, 2023

BUY
$2.13 - $5.55 $36,152 - $94,200
16,973 Added 0.52%
3,265,631 $7.41 Million
Q2 2023

Aug 14, 2023

BUY
$3.6 - $5.25 $1.05 Million - $1.53 Million
291,878 Added 9.87%
3,248,658 $14.2 Million
Q1 2023

May 15, 2023

BUY
$4.3 - $8.27 $18,309 - $35,213
4,258 Added 0.14%
2,956,780 $13.2 Million
Q4 2022

Feb 10, 2023

SELL
$5.66 - $8.42 $905,441 - $1.35 Million
-159,972 Reduced 5.14%
2,952,522 $24.9 Million
Q3 2022

Nov 14, 2022

BUY
$3.02 - $6.12 $4.33 Million - $8.78 Million
1,434,364 Added 85.47%
3,112,494 $19 Million
Q2 2022

Aug 12, 2022

SELL
$2.6 - $6.14 $2.53 Million - $5.99 Million
-974,994 Reduced 36.75%
1,678,130 $5.25 Million
Q1 2022

May 13, 2022

SELL
$5.08 - $9.81 $4.28 Million - $8.26 Million
-841,550 Reduced 24.08%
2,653,124 $15.1 Million
Q4 2021

Feb 14, 2022

BUY
$8.55 - $111.89 $204,481 - $2.68 Million
23,916 Added 0.69%
3,494,674 $34.2 Million
Q3 2021

Nov 12, 2021

BUY
$76.53 - $110.43 $4.08 Million - $5.89 Million
53,313 Added 1.56%
3,470,758 $367 Million
Q2 2021

Aug 13, 2021

BUY
$85.37 - $114.1 $292 Million - $390 Million
3,417,445 New
3,417,445 $292 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $79.6M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.